During the past decade, J.K.Cancer Institute conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "J.K.Cancer Institute" #1 collaborator was "Merck Ltd., India" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "J.K.Cancer Institute" are "Breast Neoplasms" (1 trials) and "Carcinoma, Squamous Cell" (1 trials). Many other conditions were trialed in "J.K.Cancer Institute" in a lesser frequency.

Most popular intervention types in "J.K.Cancer Institute" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Cetuximab" (1 trials) and "Eribulin Mesylate" (1 trials). Other intervention names were less common.

The vast majority of trials in "J.K.Cancer Institute" are 1 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "J.K.Cancer Institute". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in J.K.Cancer Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in J.K.Cancer Institute, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".